Bausch + Lomb Corporation (BLCO)

NYSE: BLCO · IEX Real-Time Price · USD
17.54
+0.13 (0.75%)
Feb 2, 2023, 9:50 AM EST - Market open
0.75%
Market Cap 6.15B
Revenue (ttm) 3.77B
Net Income (ttm) 58.00M
Shares Out 350.00M
EPS (ttm) 0.17
PE Ratio 102.41
Forward PE 23.31
Dividend n/a
Ex-Dividend Date n/a
Volume 11,865
Open 17.15
Previous Close 17.41
Day's Range 17.45 - 17.75
52-Week Range 12.20 - 20.20
Beta n/a
Analysts Buy
Price Target 19.89 (+13.4%)
Earnings Date Feb 22, 2023

About BLCO

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. ... [Read more]

Sector Healthcare
IPO Date May 6, 2022
Employees 12,800
Stock Exchange NYSE
Ticker Symbol BLCO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for BLCO stock is "Buy." The 12-month stock price forecast is $19.89, which is an increase of 13.40% from the latest price.

Price Target
$19.89
(13.40% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb's VISUDYNE® (Verteporfin for Injection)

VAUGHAN, Ontario & TAMPERE, Finland--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live...

Other symbols: BHC
1 day ago - Business Wire

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will relea...

Other symbols: BHC
1 week ago - Business Wire

Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today anno...

3 weeks ago - Business Wire

Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live ...

3 weeks ago - Business Wire

Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today ann...

Other symbols: BHC
1 month ago - Business Wire

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

VAUGHAN, Ontario & HEIDELBERG, Germany--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to l...

1 month ago - Business Wire

Bausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness Month

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Glauco...

1 month ago - Business Wire

Bausch + Lomb Amends CEO Separation Agreement

VAUGHAN, ON , Dec. 22, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to...

1 month ago - PRNewsWire

Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating Drops

Provides Lenses Up to Eight Hours of Moisture* VAUGHAN, ON , Dec. 13, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated t...

1 month ago - PRNewsWire

Bausch + Lomb's ONE by ONE and Biotrue® Eye Care Recycling Programs Win Gold for Most Environmentally Friendly Service of the Year from Best in Biz Awards

VAUGHAN, ON , Dec. 12, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, tod...

1 month ago - PRNewsWire

Bausch + Lomb's Biotrue® Hydration Plus Multi-Purpose Solution Receives Product of the Year Award from Business Intelligence Group's 2022 BIG Awards for Business

VAUGHAN, ON , Nov. 29, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, tod...

2 months ago - PRNewsWire

Bausch + Lomb Reports More Than 58 Million Units of Contact Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

VAUGHAN, ON , Nov. 15, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, tod...

2 months ago - PRNewsWire

Bausch + Lomb Announces Participation at the 5th Annual Evercore ISI HealthCONx Conference

VAUGHAN, ON , Nov. 7, 2022 /PRNewswire/ -- Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, tod...

3 months ago - PRNewsWire

Bausch + Lomb beats earnings expectations in Q3

Bausch & Lomb Corp. BLCO, +0.63% said Wednesday that it had a loss of $18 million, or 5 cents per share, in the first quarter of 2022, after a gain of $60 million, or 17 cents per share, in the same q...

3 months ago - Market Watch

Bausch + Lomb Announces Third-Quarter 2022 Results

Third-Quarter 2022 Financial Results Revenues of $942 Million GAAP Net Loss Attributable to Bausch + Lomb Corporation of $18 Million Adjusted EBITDA (non-GAAP) 1  of $187 Million GAAP Cash Flow from O...

3 months ago - PRNewsWire

Bausch + Lomb #LUMIFYEyeDance Challenge Wins 2022 Public Relations and Marketing Excellence Award for External Campaign of the Year from Business Intelligence Group

VAUGHAN, ON , Nov. 1, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, toda...

3 months ago - PRNewsWire

Bausch + Lomb Introduces Project Watson™ Health Care Products for Dogs

New Products Will Focus on Dogs' Eyes, Ears and Overall Wellbeing VAUGHAN, ON , Oct. 24, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health ...

3 months ago - PRNewsWire

Bausch + Lomb Announces Presentation of Scientific Data and Analyses Evaluating Biotrue® Hydration Plus Multi-Purpose Solution at American Academy of Optometry Annual Meeting

Four Poster Presentations Will Include Research on Company's Latest Solution That Provides More Moisture on Lenses for Patients1 Bausch + Lomb Will Also Sponsor Nine Educational Events VAUGHAN, Ontari...

3 months ago - PRNewsWire

Bausch + Lomb Will Release Third-Quarter 2022 Financial Results on November 2

VAUGHAN, ON , Oct. 4, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, will...

4 months ago - PRNewsWire

Bausch + Lomb Introduces Enhanced Ocuvite® Adult 50+ Eye Vitamin Formulation With Vitamin D

VAUGHAN, ON , Oct. 3, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, toda...

4 months ago - PRNewsWire

Bausch + Lomb Will Present Scientific Data and Analyses During World Cornea Congress

One Podium and Two Poster Presentations Will Highlight Pre-Clinical and Clinical Data for Investigational Treatment NOV03, as well as Data from Company's Unique ARMOR Surveillance Study VAUGHAN, ON , ...

4 months ago - PRNewsWire

Bausch + Lomb Will Present New Scientific Data and Analyses During the American Academy of Ophthalmology Annual Meeting

Bausch + Lomb Will Sponsor Two Educational Events on Dry Eye Disease VAUGHAN, ON , Sept. 26, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye hea...

4 months ago - PRNewsWire

Bausch + Lomb Announces Webinar for Eye Care Professionals on New AREDS2 Study Findings

VAUGHAN, ON , Sept. 21, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, to...

4 months ago - PRNewsWire

Recent Investments By Top Activist Investors Include Bausch + Lomb, Twitter, BBBY & GameStop - Buyers Beware

Activist investors purchase a majority of publicly traded shares in companies they believe need to be improved. It doesn't always work out for the company or its shareholders, so let's examine what in...

Other symbols: BHCGME
4 months ago - Forbes

First Annual Bausch + Lomb Sponsored Visionary Report Spotlights Nation's 'Blind Spots' on Age-related Macular Degeneration, a Leading Cause of Vision Loss for People 50+

New Report Reveals Vision Loss a Concern for Aging Americans Surveyed, But Majority Are Unaware Age-related Macular Degeneration Is a Leading Cause of Blindness VAUGHAN, Ontario , Sept. 13, 2022 /PRNe...

5 months ago - PRNewsWire